Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal
Catalent stock rose following news Novo Holdings, the parent of Wegovy maker Novo Nordisk, will buy the syringe maker for $16.5 billion in an all-cash deal.
( 1
min )